Open AccessDetection of Gram Negative Bacilli Producing Extended Spectrum Beta Lactamase on Intensive Care Unit at Tertiary Care Hospital
Author(s) -
M. Nishanthy,
Chitralekha Saikumar
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i23b31413
Subject(s) - bacilli , microbiology and biotechnology , ciprofloxacin , cephalosporin , antibiotics , meropenem , medicine , amikacin , antibiotic resistance , drug resistance , sputum , gentamicin , biology , bacteria , tuberculosis , pathology , genetics
Antimicrobial resistance is a budding threat worldwide. The every class of antibiotic agents must have resistance mechanisms.The principal mechanism for resistance to the β-lactam antibiotics in gram-negative bacteria is the production of β-lactamase. The creation of extended-spectrum β-lactamases (ESBLs) is a vital mechanism which is responsible for the resistance to the cephalosporins. During the last 2 decades, ESBL producing gram-negative bacilli have arose as a major problem in many settings. Resistance to 3rd generation cephalosporins by attainment and manifestation of extended spectrum beta lactamase (ESBL) enzymes among gram-negative bacilli is on a rise. To isolate the ESBL strains from various clinical samples in ICU. To find out the prevalence of ESBL producing gram negative bacilli during the period of December 2017 - December 2018 in the Intensive care unit of Sree Balaji Medical College and Hospital. Totally 27 out of 139 gram negative bacilli (19.42%) were found to be ESBL producers. ESBL triggering gram negative bacilli spiteful the biological sample like blood, urine, wound swab, sputum were 36.36%, 16.00%, 10.00%, 9.09% individually Though Meropenem is 100% sensitive to all ESBL beginning gram negative bacilli, but still sensitivity also witnessed with some cheaper drugs like Cotrimoxazole (33.33%), Amikacin (48.14%), Gentamicin (40.7%), Ciprofloxacin (22.22%). Hence we care and will provide an analysis and treatment for affected patients with Extended Spectrum Beta Lactamase producing organisms.